Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01935830 · ClinicalTrials.gov registry record · Early Phase 1
LAAM-HAART PET Imaging
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT01935830 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 10 participants.
The verdict
NCT01935830, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effects of the antiretroviral drugs efavirenz and ritonavir on human brain LAAM disposition in vivo.
Interventions
- DRUG Ritonavir
- DRUG Efavirenz
- RADIATION [11c] LAAM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01935830
The ClinicalTrials.gov registry entry for NCT01935830 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ritonavir is the first listed.
NCT01935830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01935830 about?
NCT01935830 is a clinical study titled "LAAM-HAART PET Imaging". The purpose of this study is to determine the effects of the antiretroviral drugs efavirenz and ritonavir on human brain LAAM disposition in vivo.
What is the current status of trial NCT01935830?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2013-08. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01935830?
The interventions under investigation include: Ritonavir (DRUG), Efavirenz (DRUG), [11c] LAAM (RADIATION).
Who is sponsoring clinical trial NCT01935830?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.